Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Valsartan amlodipine capsule and preparation method thereof

A technology of valsartan and amlodipine capsules and amlodipine besylate, which is applied in the technical field of improvement of oral solid preparations, and can solve the problems of slow release, inability to solve disintegration and dissolution, etc.

Inactive Publication Date: 2011-04-27
林海平
View PDF5 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when valsartan and amlodipine besylate are mixed in a certain proportion, especially in high doses, and then packed into capsules, after the capsule shell disintegrates in the dissolution medium, valsartan and amlodipine besylate stick together into hard lumps, Slow release; disintegration and dissolution problems cannot be solved even after being made into granules separately and mixed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Valsartan amlodipine capsule and preparation method thereof
  • Valsartan amlodipine capsule and preparation method thereof
  • Valsartan amlodipine capsule and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Valsartan 160g

[0033] Amlodipine besylate 13.86g

[0034] Microcrystalline Cellulose 106g

[0035] Crospovidone 50g

[0036] Silica 0.65g

[0037]

[0038] Makes 1000 capsules

[0039] Amlodipine besylate, crospovidone, microcrystalline cellulose, valsartan, and silicon dioxide in the prescribed amount are added to the mixer in sequence, fully mixed, and filled into capsules.

Embodiment 2

[0041] Valsartan 160g

[0042] Amlodipine besylate 6.93g

[0043]Microcrystalline Cellulose 50g

[0044] Crospovidone 40g

[0045] Silica 0.26g

[0046]

[0047] Makes 1000 capsules

[0048] Amlodipine besylate, crospovidone, microcrystalline cellulose, valsartan, and silicon dioxide in the prescribed amount are added to the mixer in sequence, fully mixed, and filled into capsules.

Embodiment 3

[0050] Valsartan 320g

[0051] Amlodipine besylate (calculated as amlodipine) 13.86g

[0052] Microcrystalline Cellulose 60g

[0053] Crospovidone 80g

[0054] Silica 1.0g

[0055]

[0056] Makes 1000 capsules

[0057] Amlodipine besylate, crospovidone, microcrystalline cellulose, valsartan, and silicon dioxide in the prescribed amount are added to the mixer in sequence, fully mixed, and filled into capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a capsule containing valsartan and amlodipine besylate, which is prepared from high-dose valsartan and amlodipine besylate, disintegrating agent crospovidone, filling agent microcrystalline cellulose and lubricating agent silicondioxide. The problem that the compound preparation contianing a high dose of valsartan and amlodipine besylate is not easy to disintegrate and dissolve is solved by adopting the conventional process and equipment of powder mixing and direct capsule filling without using special equipment and the bilayer tablet process.

Description

Technical field: [0001] The invention relates to an oral pharmaceutical composition containing valsartan and amlodipine besylate, and relates to an improved technology for an oral solid preparation of a compound preparation of valsartan and amlodipine besylate. Background technique: [0002] The incidence of hypertension remains high, and there are about one billion hypertensive patients in the world. Blood pressure cannot be controlled within the range of the target value, which can induce cardiovascular disease, kidney disease and metabolic disease. Controlling blood pressure levels can effectively reduce the incidence and mortality of cardiovascular events. Although various antihypertensive drugs are currently on the market, 40% to 80% of hypertensive patients still cannot achieve the prescribed blood pressure control target value, mainly due to poor patient compliance or insufficient medication. Current treatment guidelines recommend the use of compound preparations to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4422A61K31/41A61K47/32A61K47/38A61K47/04A61K9/48A61P9/12
Inventor 林海平
Owner 林海平
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com